---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-131979"
form_type: "8-K"
ticker: "OSUR"
cik: "0001116463"
company_name: "ORASURE TECHNOLOGIES INC"
filed_at: "2026-03-30T23:59:59+00:00"
generated_at: "2026-05-15T08:20:18.965700+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# OraSure responds to Altai Capital, citing 40% TSR outperformance under CEO; $199M cash; product catalysts ahead

## Summary
- Total shareholder return outperformed peer median by ~40% during CEO Carrie Eglinton Manner's tenure (since June 2022).
- Cash balance of $199M, no debt; $40M share repurchase program initiated in 2025 at avg price $2.85.
- Gross margin improved 260bps over 3 years to 43%; SG&A reduced 37% to $73.8M; workforce cut ~40%.
- Near-term catalysts: Colli-Pe urine collection device (~$0.5B TAM) and Sherlock CT/NG self-test (~$1.5B TAM).
- Expects operating cash flow breakeven entering 2027; new products launching in 2026.

## SEC filing metadata
- accession: 0001193125-26-131979
- form_type: 8-K
- ticker: OSUR
- cik: 0001116463
- company_name: ORASURE TECHNOLOGIES INC
- filed_at: 2026-03-30T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1116463/000119312526131979/0001193125-26-131979-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1116463/000119312526131979/d138279d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-131979
- JSON: https://secwatch.observer/filing/0001193125-26-131979.json
- Plain text: https://secwatch.observer/filing/0001193125-26-131979.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.